Search for a report

NORTH AMERICA ANTI-RHEUMATICS MARKET FORECAST 2020-2028

  • You are here:
  • Home
  • Downloads
  • NORTH AMERICA ANTI-RHEUMATICS MARKET FORECAST 2020-2028

NORTH AMERICA ANTI-RHEUMATICS MARKET FORECAST 2020-2028

The North American anti-rheumatics market is anticipated to register a CAGR of 2.63% over the estimated period of 2020-2028. The factors boosting the market growth in the region are the rising prevalence of rheumatoid arthritis and an increase in the geriatric population in the region. The growth of the North America anti-rheumatics market is further analyzed on the basis of the markets situated in the United States and Canada.

NORTH AMERICA ANTI-RHEUMATICS MARKET FORECAST 2020-2028

North America Anti-rheumatics Market by Type (Prescription-based Drugs, Over-the-counter Drugs) by Drug Class (Disease Modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drug Class) and by Geography.

Request free sample

The North American anti-rheumatics market is anticipated to register a CAGR of 2.63% over the estimated period of 2020-2028. The factors boosting the market growth in the region are the rising prevalence of rheumatoid arthritis and an increase in the geriatric population in the region.
North America Anti-rheumatics MarketThe growth of the North America anti-rheumatics market is further analyzed on the basis of the markets situated in the United States and Canada. In the US, patients are generally referred by their primary care physician to a rheumatologist, who officially diagnoses the disease and manages the patient throughout the course of their disease. If systematic manifestations of rheumatoid arthritis arise, the patient may be referred to another specialist, and the PCP continues to take care of the patient’s overall health. The doctors in the US refer to a number of tests to confirm the diagnosis of rheumatoid arthritis, and also tries to find if signs of inflammatory arthritis. The tests performed are blood tests for RF, ESR, anti-CCP, CRP, and a blood differential/CBC. Other common tests are X-ray, joint fluid evaluation, and MRI occasionally. Further, according to the CDCP, from 2013 TO 2015, annually, about 22% of US adults are diagnosed with some form of arthritis, rheumatoid arthritis, lupus, gout, or fibromyalgia. The prevalence of rheumatoid arthritis in the US is predicted to drive market growth.

Abbott Laboratories, headquartered in Abbott Park, Illinois, the US, is a pharmaceutical company that develops, manufactures, and markets a wide range of healthcare products. The company operates in India, the Netherlands, China, the US, Switzerland, Japan, and other countries. In June 2019, Abbott, together with CARE and Abbott Fund, began a three-year partnership for preventing and managing non-communicable diseases.

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES
      • MARKET OVERVIEW
    3. MARKET DYNAMICS
      • MARKET DEFINITION
      •    KEY DRIVERS
        • RISING GERIATRIC POPULATION
        • SURGE IN THE PREVALENCE OF RHEUMATOID ARTHRITIS DISEASE
        • GROWING HEALTHCARE EXPENDITURE
      •    KEY RESTRAINTS
        • PATENT EXPIRATIONS
        • LACK OF REGULATORY GUIDELINES FOR BIOSIMILARS WILL DELAY THEIR AVAILABILITY IN SOME REGIONS
        • LESS EXPENSIVE ALTERNATIVES
    1. KEY ANALYTICS
      •    PORTER’S FIVE FORCE ANALYSIS
        • THREAT OF NEW ENTRY
        • THREAT OF SUBSTITUTION
        • BUYER’S POWER
        • SUPPLIER’S POWER
        • COMPETITIVE RIVALRY
      • ETIOLOGY OF RHEUMATOID ARTHRITIS (RA)
      • SYMPTOMS OF RHEUMATOID ARTHRITIS
      • RISK FACTORS ASSOCIATED WITH RHEUMATOID ARTHRITIS
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
      • KEY INVESTMENT INSIGHTS
    2. MARKET BY TYPE
      • PRESCRIPTION-BASED DRUGS
      • OVER-THE-COUNTER DRUGS
    3. MARKET BY DRUG CLASS
      • DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
      • NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
      • CORTICOSTEROIDS
      • URIC ACID DRUGS
      • OTHER DRUG CLASS
    4. GEOGRAPHICAL ANALYSIS
      •    NORTH AMERICA
        • THE UNITED STATES
        • CANADA
    1. COMPANY PROFILES
      • ABBOTT LABORATORIES
      • ABBVIE INC
      • AMGEN INC
      • BECTON, DICKINSON & COMPANY (BD)
      • BIO-RAD LABORATORIES INC
      • BRISTOL-MYERS SQUIBB COMPANY
      • ELI LILLY & COMPANY
      • LUPIN LIMITED
      • HOFFMANN-LA ROCHE
      • JOHNSON & JOHNSON
      • MERCK & CO INC
      • NOVARTIS AG
      • PERKINELMER
      • PFIZER INC
      • UCB

    TABLE LIST

    TABLE 1: MARKET SNAPSHOT – ANTI-RHEUMATICS

    TABLE 2: COMMON SYMPTOMS OF RHEUMATOID ARTHRITIS

    TABLE 3: RISK FACTORS FOR RHEUMATOID ARTHRITIS

    TABLE 4: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 5: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 6: NORTH AMERICA PRESCRIPTION-BASED DRUGS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 7: NORTH AMERICA PRESCRIPTION-BASED DRUGS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 8: NORTH AMERICA OVER-THE-COUNTER DRUGS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 9: NORTH AMERICA OVER-THE-COUNTER DRUGS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 10: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY DRUG CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 11: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY DRUG CLASS, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 12: NORTH AMERICA DISEASE MODIFYING ANTI-RHEUMATIC DRUGS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 13: NORTH AMERICA DISEASE MODIFYING ANTI-RHEUMATIC DRUGS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 14: NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 15: NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 16: NORTH AMERICA CORTICOSTEROIDS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 17: NORTH AMERICA CORTICOSTEROIDS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 18: NORTH AMERICA URIC ACID DRUGS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 19: NORTH AMERICA URIC ACID DRUGS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 20: NORTH AMERICA OTHER DRUG CLASS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 21: NORTH AMERICA OTHER DRUG CLASS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 22: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 23: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    FIGURE LIST

    FIGURE 1: PORTER’S FIVE FORCE ANALYSIS

    FIGURE 2: OPPORTUNITY MATRIX

    FIGURE 3: VENDOR LANDSCAPE

    FIGURE 4: KEY INVESTMENT INSIGHTS

    FIGURE 5: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY TYPE, IN 2019

    FIGURE 6: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY PRESCRIPTION-BASED DRUGS, 2020-2028 (IN $ MILLION)

    FIGURE 7: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY OVER-THE-COUNTER DRUGS, 2020-2028 (IN $ MILLION)

    FIGURE 8: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY DRUG CLASS, IN 2019

    FIGURE 9: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY DISEASE MODIFYING ANTI-RHEUMATIC DRUGS, 2020-2028 (IN $ MILLION)

    FIGURE 10: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, 2020-2028 (IN $ MILLION)

    FIGURE 11: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY CORTICOSTEROIDS, 2020-2028 (IN $ MILLION)

    FIGURE 12: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY URIC ACID DRUGS, 2020-2028 (IN $ MILLION)

    FIGURE 13: NORTH AMERICA ANTI-RHEUMATICS MARKET, BY OTHER DRUG CLASS, 2020-2028 (IN $ MILLION)

    FIGURE 14: NORTH AMERICA ANTI-RHEUMATICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)

    FIGURE 15: THE UNITED STATES ANTI-RHEUMATICS MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 16: CANADA ANTI-RHEUMATICS MARKET, 2020-2028 (IN $ MILLION)

    1. GEOGRAPHICAL ANALYSIS
      •    NORTH AMERICA
        • THE UNITED STATES
        • CANADA
    1. MARKET BY TYPE
      • PRESCRIPTION-BASED DRUGS
      • OVER-THE-COUNTER DRUGS
    2. MARKET BY DRUG CLASS
      • DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
      • NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
      • CORTICOSTEROIDS
      • URIC ACID DRUGS
      • OTHER DRUG CLASS

    To request a free sample copy of this report, please complete the form below :
    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


      Choose License Type

      Buy Now